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Honey has been used since long time both in medical and domestic needs, but only recently the antioxidant property of it came to
limelight. The fact that antioxidants have several preventative effects against different diseases, such as cancer, coronary diseases,
inflammatory disorders, neurological degeneration, and aging, led to search for food rich in antioxidants. Chemoprevention uses
various dietary agents rich in phytochemicals which serve as antioxidants. With increasing demand for antioxidant supply in the
food, honey had gained vitality since it is rich in phenolic compounds and other antioxidants like ascorbic acid, amino acids,
and proteins. Some simple and polyphenols found in honey, namely, caffeic acid (CA), caffeic acid phenyl esters (CAPE), Chrysin
(CR), Galangin (GA), Quercetin (QU), Kaempferol (KP), Acacetin (AC), Pinocembrin (PC), Pinobanksin (PB), and Apigenin
(AP), have evolved as promising pharmacological agents in treatment of cancer. In this review, we reviewed the antiproliferative
and molecular mechanisms of honey and above-mentioned polyphenols in various cancer cell lines.
Copyright © 2009 S. K. Jaganathan and M. Mandal. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. Introduction
Prevention is better than cure and this is very true in case
of cancer. Chemoprevention was defined as the adminis-
tration of agents to prevent induction, to inhibit or to
delay the progression of cancer [1], or as the inhibi-
tion or reversal of carcinogenesis at a premalignant stage
[2]. Chemoprevention utilizes appropriate pharmacological
agents [3, 4] or of dietary agents, consumed in diverse
forms like macronutrients, micronutrients, or nonnutritive
phytochemicals [5–7]. Consumption of antioxidants has
been related to the several preventative effects against
different diseases such as cancer, coronary diseases, inflam-
matory disorders, neurological degeneration, and aging
[8, 9] led to search for natural foods rich in antioxi-
dants. Although honey has been used since long time,
only recently its antioxidant property came to limelight
[10]. Honey has some minor constituents compared to its
major sugar level, which is believed to have antioxidant
properties [11, 12]. Some to mention were flavonoids
and phenolic acids [13, 14], certain enzymes (glucose
oxidase, catalase), ascorbic acid [15], carotenoid-like sub-
stances [16], organic acids [13], amino acids, and proteins
[17].
Phytochemicals are one wide class of nutraceuticals
found in plants which are extensively researched by scientists
for their health-promoting potential. Honey has a wide
range of phytochemicals including polyphenols which act as
antioxidants. Polyphenols and phenolic acids found in the
honey vary according to the geographical and climatic con-
ditions. Some of them were reported as a specific marker for
the botanical origin of the honey. Considerable differences in
both composition and content of phenolic compounds have
been found in different unifloral honeys [18]. Terpenes, ben-
zyl alcohol, 3, 5-dimethoxy-4-hydroxybenzoic acid (syringic
acid), methyl 3, 5-dimethoxy-4-hydroxybenzoate (methyl
syringate), 3, 4, 5-trimethoxybenzoic acid, 2-hydroxy-3-
phenylpropionic acid, 2-hydroxybenzoic acid and 1, 4-
dihydroxybenzene are some of the phytochemicals ascribed
for the antimicrobial activity of honey [19]. Among these
phytochemicals, polyphenols were reported to have antipro-
liferative potential. In this review, we summarized the
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compositional chemistry and antiproliferative potential of
crude honey and some of its important polyphenols in
various cancer cells.
2. Source and Compositional
Chemistry of Honey
Honey bees collect the nectar from various floral sources
and store it as honey which serves as food for bees during
winter. Honey bees make a journey of nearly 55,000 miles
to gather nectar from approximately 2 million flowers for
accumulating one pound of honey. In the bee-hive, we can
find thee types of bees namely the queen, drone and worker
bees. Among them, only worker bees collect and regurgitate
the nectar number of times, in order to partially digest
the nectar, before storing in the honey comb. During the
collection of nectar, pollen can be included into the honey
though variety of ways. As the honeybee visits the flower
in hunt of nectar, some of the flower’s pollen falls into the
nectar collected by the bee and stored in the stomach which
will be regurgitated along with nectar. Moreover some pollen
grains often attach themselves to the various parts of the
honey bee body like legs, antenna, hairs, and also in the
eyes of visiting bees which will get entangled in the hive and
thereby paving entry into the honey. Airborne pollen is also
another route of entry for pollen into the honey which got
transferred though wind currents. Honey bees use its wings
to fan the honey comb, to evaporate most of the water from
nectar thereby avoiding the fermentation of honey. The color
of the honey collected by the bees varies according to the
floral source and its mineral content, which usually ranges
fromwater white to dark amber. Flavor of the honey depends
upon the color, generally the darker the honey the stronger
the flavor and quality (Figure 1). It has been reported more
than 300 unique varieties of honey depending upon the floral
sources from United States alone. Honey mainly composed
of sugars and water which accounts roughly 79.6% and
17.2%, respectively, (Figure 2). Major sugars of honey are
levulose and dextrose which constitutes 38.19% and 31.28%
correspondingly, remaining is the sucrose 1.3% and maltose
7.3%. Honey minor constituents include acids (0.57%),
protein (0.266%), nitrogen (0.043%), amino acids (0.1%),
a little amount of minerals (0.17%), and a number of
other minute quantities of components like pigments, flavor
and aroma substances, phenolics compounds, colloids, sugar
alcohols and vitamins which all together accounts for the
2.1% of whole honey composition [20, 21].
3. Anticancerous Property of Crude Honey
Few researchers studied the effect of crude honey in cancer.
In a recent research conducted by Jaganathan et al. illustrated
the apoptosis inducing ability of the honey. They showed
honey induced apoptosis in human colon cancer cells
by arresting the cells at subG1 phase. Honey possessing
higher phenolic and tryptophan content was more potent
in inhibiting the colon cancer cell proliferation. Finally they
demonstrated that honey induced apoptosis was associated
Figure 1: Color variation of honey samples from dark amber (top-
left dish) to whitish yellow (bottom-right dish). Flavor of the honey
depends upon the color, generally the darker the honey the stronger
the flavor and quality.
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Figure 2: Pie-chart of Honey composition indicating the percent-
age share of various sugars, water and other minor constituents.
with Caspase-3 activation and PARP cleavage. DNA frag-
mentation assay in HT 29 cells displayed typical ladder
pattern confirming apoptosis [22]. Research by Orsolic et al.
showed that water soluble derivative of propolis and its
associated phenolic compounds have antimetastatic effect
on the tumor mice models before and after the injection
of tumor cells. Further they showed that honey could exert
antimetastatic effect when given before tumor cell injection
[23]. In the study conducted by Tarek et al. honey was
proven to be a very effective agent for repressing the growth
of bladder cancer cell lines (T24, RT4, 253J, and MBT-
2) in vitro. Further honey was found to be effective when
administered intralesionally or orally in the MBT-2 bladder
cancer implantation models. There was also a significant
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difference between the final tumor volume (P < .05) in
the Intra lesion (IL) honey-treated groups (IL 6% honey)
compared to the IL saline group. The difference between
the final tumor volume or weight in the IL saline group
and the control group was not significant [24]. Research
conducted by Gribel and Pashinskii indicated that honey
exhibited moderate antitumor and significant antimetastatic
effects in five different strains of rat and mouse tumors.
Moreover, the antitumor activity of certain chemotherapeu-
tic drugs such as 5-fluorouracil and cyclophosphamide was
also facilitated by the honey [25]. It has been elucidated
that polyphenols are anticarcinogenic, antiinflammatory,
antiatherogenic, antithombotic, immune modulating and
also act as antioxidants [26–31]. Hence antitumor properties
of honey could be attributed to the polyphenols found in the
honey. Moreover, with the evolution of extraction procedure
for various polyphenols, which had been attributed with
anticancerous property of honey, researchers concentrated
on the polyphenolic compounds extracted from the honey
rather than crude honey itself.
Phenolic compounds or polyphenols are the important
groups of compounds occurring in plants, where they are
widely distributed, comprising at least 8000 different known
structures [32]. It is also produced by plants as a secondary
metabolite. Some of these phenolic compounds were also
available in the honey. In general, phenolic compounds can
be divided into at least 10 types depending upon their
basic structure: simple phenols, phenolic acids, coumarins
and isocoumarins, naphthoquinones, xanthones, stilbenes,
anthaquinones, flavonoids and lignins. Flavonoids constitute
the most important polyphenolic class, with more than
5000 compounds already described. Flavonoids are the
natural antioxidants exhibiting a wide range of biological
effects including antibacterial, antiinflammatory, antialler-
gic, antithombotic and vasodilatory actions [26].
Various polyphenols were reported in honey. Polyphe-
nols found in the honey was used as a marker for particular
type of honey, for example, flavanol kaempferol as an
indicator for rosemary honey [33, 34] and quercetin for
sunflower honey [35]. The hydroxy-cinnamates like caffeic
acid, ferulic acid and p-coumaric acid have been found in the
chest-nut honey [36]. Characteristic flavonoids of propolis
like pinocembrin, pinobanksin and chrysin were also found
in the most European honey samples [35]. In this review,
we concentrated on the some major polyphenols available in
the honey which exhibited antiproliferative effect on various
cancer cell lines. The list of compounds (refer Table 1 for
figures) reviewed for their anticancerous activity is Caffeic
acid (CA), Caffeic acid phenyl ester (CAPEs), Chrysin (CR),
Galangin (GA), Quercetin (QU), Acacetin (AC), Kaempferol
(KF), Pinocembrin (PC), Pinobanksin (PB), and Apigenin
(AP).
3.1. Role of Individual Polyphenols in Cancer
3.1.1. Effect of Caffeic Acid and Its Esters in Animal Model and
Cancer Cell Lines. Caffeic acid is a naturally occurring phe-
nolic compound present in the honey. Research conducted
Table 1: Molecular representation of Polyphenols found in the
honey.
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by Hirose et al. studied the carcinogenicity of low dietary
levels of the antioxidants like butylated hydroxyanisole
(BHA), caffeic acid, sesamol, 4-methoxyphenol (4-MP) and
catechol. These antioxidants were eminent target of the fore-
stomach or glandular stomach and these were examined for
their predominant effects in alone or in combinations, for
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a two-year period experiment. Carcinogenicity study was
undertaken in groups of 30-31 male F344 rats, by treating
with 0.4% BHA, 0.4% caffeic acid, 0.4% sesamol, 0.4% 4-
MP and 0.16% catechol either alone or in combination
for up to 104 weeks and then killed. The ultimate average
body weights of rats having basal diets were higher than
those treated with antioxidants alone, and were the lowest
in the combinational groups. Moreover the relative liver
and/or kidney weights were greater than before in the
BHA, sesamol, catechol and combination groups. It led
to the conclusion, that the occurrences and frequencies
of fore-stomach histopathological lesion were increased by
exposing to antioxidants except in the case of BHA. The
incidences and/or multiplicities of forestomach papillary or
nodular (PN) hyperplasia were appreciably increased in the
groups treated with 4-methoxyphenol, caffeic acid and the
antioxidants in combination, as compared with the basal
diet group. Studies on medium-term multiorgan carcino-
genesis model, suggested an increase in the occurrence of
fore-stomach papillomas in each high-dose group and no
synergistic effect was observed in combinations. In the low
dose case, the incidence of fore-stomach papillomas was
significantly increased only in the combination group. The
effect on the other organs particularly colon tumors, was
significantly decreased only in the high-dose combination
group. Hence it can be inferred that at low dose levels, the
phenolic compounds can exhibit additive/synergistic effect
on carcinogenesis [37]. From these early experiments, caffeic
acid is still listed under older Hazard Data sheets as a
potential carcinogen.
Rao et al. performed a detailed study by synthesiz-
ing thee caffeic acid esters namely methyl caffeate (MC),
phenylethyl caffeate (PEC) and phenylethyl dimethylcaffeate
(PEDMC) and examined them against the 3, 2′-dimethyl-4-
aminobiphenyl (DMAB, a colon and mammary carcinogen)
induced mutagenecity in Salmonella typhimurium strains TA
98 and TA 100. Both the strains of Salmonella subsisted
(survival rate >98%) concentration of about 2,500 μM CA,
150 μM MC, 70 μM PEC and 80 μM PEDMC/plate. More-
over 150 μM MC, 40–80 μM of PEDMC, 40–60 μM of PEC
significantly inhibited the DMAB-induced mutagenecity in
both strains. The outcome of these experiments placed
MC at a concentration greater than 225 μM and PEC and
PEDMC at a level greater than 60 μMwas toxic. CA exhibited
significant toxicity only at above 2500 μM concentration. In
colon cancer cell line (HT-29), cytotoxicity effect of CA, PEC,
PEDMC andMCwas evaluated. The growth inhibitory effect
of these compounds was measured after exposing cells for a
period of 48 hours. CA was found to be the least effective in
inhibiting the growth of HT-29 cells when compared to its
ester analogs. To further corroborate the growth inhibitory
effects, synthesis of polynucleotide and protein synthesis
after incubating the HT-29 cells with these agents for
48 hours were investigated. It has been observed that at the
concentration of 175 μM of MC, 40 μM of PEC and 60 μM of
PEDMC blocked the DNA, RNA and the protein synthesis.
Moreover ornithine decarboxylase (ODC) activity was inhib-
ited at concentrations of 150 μM MC, 40 μM PEC and 20 μM
PEDMC. Tyrosine protein kinase (TPK) activity was also
inhibited at concentrations of 100 μM of MC, 30 μM of PEC
and 20 μM of PEDMC [38]. In their follow-up studies made
by them, reported the inhibitory effects of methyl caffeate
(MC) and phenylethyl caffeate (PEC) on azoxymethane-
(AOM-)induced ornithine decarboxylase (ODC), tyrosine
protein kinase (TPK) and arachidonic acid metabolism in
liver and colonic mucosa of male F344 rats. They depicted
the inhibitory effects of caffeic acid, MC, PEC, phenylethyl-
3-methylcaffeate (PEMC), and phenylethyl dimethyl caffeate
(PEDMC) on in vitro arachidonic acid metabolism in liver
and colonic mucosa. Finally they investigated the effects
of PEC, PEMC, and PEDMC on AOM-induced aberrant
crypt foci (ACF) formation in the colon of F344 rats. For a
period of five weeks, groups of F334 rats were fed with diets
containing 600 ppm of MC or PEC for biochemical studies
and 500 ppm of PEC, PEMC or PEDMC for ACF studies.
After two weeks, subcutaneous injection of AOM was given
once in a week for two consecutive weeks, for all animals
except the vehicle-treated groups. Biochemical studies were
performed by sacrificing the animal after 5 days. In case of
ACF study, F334 rats were sacrificed after 9 weeks latter for
analyzing ACF in colon. The colonic mucosa and liver of the
rats were analyzed for the orinithine decarboxylase activity,
tyrosine protein kinase activity (TPK), lipoxygenase and
cyclooxygenase metabolites. PEC diet significantly inhibited
AOM-induced ODC and TPK activities in liver and colon.
It had been observed that PEC diet significantly repressed
the AOM-induced lipoxygenase metabolites 8(S)- and 12(S)-
hydroxyeicosatetraenoic acid (HETE). The animals fed the
MC diet exhibited a moderate inhibitory effect on ODC
and 5(S)-, 8(S)-, 12(S)-, and 15(S)-HETEs and a significant
effect on colonic TPK activity. However, both the MC
and PEC diets showed no significant inhibitory effects on
cyclooxygenase metabolism. ACF were significantly inhibited
in the animals fed with PEC (55%), PEMC (82%), or
PEDMC (81%). The results of the study indicated that
PEC, PEMC, and PEDMC present in the honey, inhibited
AOM-induced colonic preneoplastic lesions, ODC, TPK,
and lipoxygenase activity, which were relevant to the colon
carcinogenesis [39].
Huang et al. showed the strong repressive effect of
CAPE application on 12-0-tetradecanoylphorbol-13-acetate-
(TPA-)induced tumor promotion and production of 5-
hydroxymethyl-2′-deoxyuridine (HMdU) in the deoxyri-
bonucleic acid (DNA) of the mouse skin. They established
the inhibitory effect of CAPE on TPA-induced tumor
promotion by topical application of CAPE in CD-I mice
previously treated with 7, 12-dimethylbenz[a]anthracene
(DMBA). They applied CAPE in concentration ranging from
1, 10, 100, or 3000 nmol together with 5 nmol of TPA twice
a week for 20 weeks. At the above concentrations, CAPE
inhibited the number of skin papillomas by 24, 30, 45 and
70% and tumor size per mouse was decreased by 42%, 66%,
53%, and 74%, respectively. Moreover topical application of
5 nmol of TPA twice weekly for 20 weeks to mice produced
an average of 12.6 HMdU residues per 104 normal bases
in epidermal DNA. Topical application of 1, 10, 100, or
3000 nmol of CAPE along with 5 nmol of TPA twice weekly
for 20 weeks to DMBA-initiated mice decreased the levels
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of HMdU in epidermal DNA by 40–93%. CAPE at 1.25,
2.5, 5, 10, or 20 μM inhibited the incorporation of [3H]-
thymidine into DNA in cultured HeLa cells by 32%, 44%,
66%, 79%, and 95% respectively. Similarly incorporation of
[3H]-uridine into RNA was inhibited by 39%, 43%, 58%,
64%, and 75% whereas incorporation of [3H]-leucine into
protein was inhibited by 29%, 30%, 37%, 32%, or 47%,
respectively. These results indicated that CAPE is a potent
inhibitor of DNA synthesis but it is somewhat less effective in
inhibiting RNA synthesis and it is least effective in inhibiting
the protein synthesis [40].
The molecular basis of CAPE action was elucidated by
Natrajan et al. Since NF-κB has a role in these activities, they
examined the effect of CAPE on this transcription factor in
an exhaustive manner. They preincubated the U-937 cells
with CAPE with various concentrations for 2 hours before
treating with TNF (0.1 nM) for 15 minutes. CAPE inhibited
the TNF-dependent activation of NF-κB in a dose-dependent
manner with maximum effect occurring at 25 μg/mL. NF-
κB activation induced by the phorbol ester, phorbol-12-
myristate 13-acetate (PMA), ceramide, okadaic acid and
hydrogen peroxide was also inhibited by CAPE. It prevented
the translocation of p-65 subunit of NF-κB to the nucleus
without affecting the TNF-induced IκBα degradation. It does
not showed any inhibitory effect on the other transcription
factors like AP-1, TFIID and oct-1. To study further pre-
cisely about the role of CAPE in inhibiting NF-κB various
structural analogues of CAPE were examined. It has been
configured that a bicyclic, rotationally constrained, 5, 6-
dihydroxy form showed supremacy, whereas 6, 7-dihydroxy
variant was the least active in inhibiting the NF-κB. With
these findings they concluded that CAPE is a potent and a
specific inhibitor of NF-κB activation and this may provide
the molecular basis for its multiple immunomodulatory and
antiinflammatory activities of CAPE [41].
In another study initiated by Lee et al. investigated the
cytotoxicity potential of CAPE and the molecular mecha-
nism of its action in C6 glioma cells. The results of the
experiments indicated C6 glioma cells underwent internu-
cleosomal DNA fragmentation after 24 hours treatment with
CAPE (50 μM). FACS analysis of CAPE-treated C6 glioma
cells showed increasing accumulation of hypodiploid nuclei
(24% at 36 hour) in time-dependent fashion. Further results
showed that CAPE induced the release of cytochome-c from
mitochondria into the cytosol after 3 hours of treatment
resulting in the activation of caspase-3 (CPP32) from the
beginning of 3 hours. Moreover the cleavage of PARP
(substrate of CPP32) started within 12 hours after CAPE
treatment. CAPE enhanced the serine phosphoryaltion of
p53 after 0.5 hours and the protein level of p53 was increased
after 3 hours. CAPE treatment also enhanced the expression
of Bax and Bak and resulted in the reduced level of B-cell
lymphoma/leukemia-2 gene (Bcl2) protein (after 36 hours).
Moreover they reported that CAPE application activates
the extracellular signal-regulated kinase (ERKs) and p38
mitogen-activated protein kinase (p38 MAPK) in the C6
glioma cells. Further they showed that expression of p53,
phospho-serine 15 of p53, Bax and inactivate form of CPP32
were suppressed by a pretreatment of a specific p38 MAPK
inhibitor, SB203580. Hence they concluded p53 dependent
apoptosis in C-6 glioma cells were mediated by p38 MAPK
[42].
Chung et al. showed both CA and CAPE selectively
inhibited Matrix Metalloproteinases-2 (MMP-2) and MMP-
9. CAPE inhibited strongly with IC50 of 2–5 μM whereas CA
requires 10–20 μM. But MMP-1, 3, 7 and Cathepsin-K were
not completely inhibited by both of them. CA and CAPE
had a dose-dependent inhibitory effect on the proliferation
of HEPG2 cells. In HepG2 cells, CA at the concentration of
200 μg/mL reduced the cell viability to 61% compared to the
control, and the treatment with CAPE (at low concentration
of 20 μg/mL) reduced the viability to 72% compared of the
control. CAPE and CA suppressed the MMP-9 expression,
exposed to phorbol 12-myristate 13-acetate (PMA), by
blocking the NF-κB activity in HEPG2 cells. They also con-
firmed that CA (20mg/kg) and CAPE (5mg/kg) repressed
the growth of HepG2 tumor xenografts in nude mice as
well as liver metastasis when administered subcutaneous or
orally. Finally they concluded their observation that CA and
its derivative CAPE: (1) inhibited the enzymatic activity of
MMP-9 that plays an important role in cancer invasion
and metastasis, (2) blocked the invasive potential through
the suppression of MMP-9 gene transcription by inhibiting
NF-κB function in PMA-stimulated HepG2 cells and (3)
suppressed the growth of HepG2 cell xenografts in nude
mice. Therefore, these two drugs were reported as strong
candidates for treatment of cancer and metastasis via dual
mechanisms (dual inhibition of metastasis-specific enzyme
activity and gene transcription) [43].
Further in a recent study initiated by Hwang et al.
investigated the effect of CAPE on tumor invasion and
metastasis in HT 1080 fibrosarcoma cells by determining
the regulation of matrix metalloproteinase’s (MMPs). HT
1080 cells were treated with increasing concentration of
CAPE and the m-RNA transcripts of MMP-2 and MMP-9
were analyzed using semi-quantitative RT-PCR. Both MMP-
2 and 9 proteins levels were significantly suppressed at
dose dependent manner. Gelatin zymography also indicated
constitutively expressed MMP-2 and 9 proteins in HT 1080
cells which gradually reduced after treating with CAPE.
To further corroborate the downregulation of MMP-2,
activation studies of pro-MMP2 were performed using
organomercuric compound, 4-aminophenylmercuric acetate
(APMA), and the result indicated the down regulation of
MMP-2 by CAPE. It has been shown that m-RNA levels of
Tissue inhibitor of matrix metalloproteinase’s (TIMPs) and
Membrane type-Matrix Metalloproteinase’s (MT-1 MMPs)
were also reduced significantly. CAPE also inhibited the cell
invasion, cell migration and colony formation of tumor cells.
Thus CAPE acts as a vital antimetastatic agent, by inhibiting
the metastatic and invasive potential of malignant cells [44].
Moreover some researchers investigated the possible
UVC (280–100 nm) protective properties of caffeic acid in
human diploid fibroblast and A-431 epidermoid cancer
cell lines. The UVC safeguarding effect of CA in two
different concentrations (55.5 μM and 166.5 μM) was clearly
illustrated both in transformed and normal cells. A marked
difference in the proliferation of normal and transformed
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cells when irradiated to UVC radiation was observed when
cell was grown in DMEM media containing CA. CA’s pro-
tective effect was distinct in the transformed cells compared
to normal cells [45]. In a sequential study by Vanisree et al.
explained protective effect of CA against UVB (280–320 nm)
radiation-induced IL-10 expression and the activation of the
Mitogen-activated Protein Kinases (MAPKs) in mouse skin.
CA inhibited the IL-10 promoter transcription, measured
using in vivo transgenic IL-10 promoter-luciferase reporter
gene base assay. IL-10 mRNA expression and protein pro-
duction in the mouse skin were significantly repressed by
CA. There have also been shown the upstream regulators
like extracellular regulated protein kinase (ERK), c-Jun N-
Terminal protein, p-38 mitogen-activated protein kinase
(p38 MAPK) and the downstream transcription factors like
activator protein (AP-1) and nuclear factor kappa B (NF-
κB) were also inhibited by CA in mouse skin. From these
experiments it was inferred that CA could be used as a topical
agent against harmful UVB irradiation [46].
3.1.2. Effect of Chrysin and Its Derivatives in Cancer Cell Lines.
Chrysin (5, 7-dihydroxyflavone) is a natural and biologically
active compound extracted from honey, plants and propolis.
It possesses potent antiinflammatory, antioxidant properties
and promotes cell death by perturbing cell cycle progression.
In a recent study conducted by Weng et al. illustrated the
molecular mechanism of action of chrysin against C6-glioma
cells. In an antiproliferation assay performed on C6 glioma
cells, chrysin inhibited the cell proliferation after 24, 48
and 72 hours. After 72 hours of incubation with 50 μM
of chrysin, 90% of cell proliferation was inhibited. Flow
cytometry analysis reported that by 30 and 50 μM treatments
after 24 hours, chrysin increased the proportion of cells in
the G1 phase of the cell cycle from 69 to 79% and 83%
and decreased the proportion of S phase cells from 11.4 to
6.1% and 2.8%, respectively. The proportion of G2/M phase
cells changed from 17.9 to 12.2% and 9.2%, after 30 and
50 μM treatments. It has been found that levels of phospho-
rylation of Retinoblastoma (Rb) protein in C6 glioma cells
decreased after treating with 30 μM of chrysin. Moreover in
chrysin-treated cells, it has been demonstrated that cyclin
dependent kinase inhibitor (p21Waf1/Cip1) levels are increased
significantly without the change in p53 protein level. To
depict the role of p38 in chrysin-mediated p21Waf1/Cip1
induction, they used p38 specific inhibitor which resulted
in the lowering of p21Waf1/Cip1 level. Furthermore they
showed that proteosome activity, cyclin dependent kinase 2
(CDK2) and 4 (CDK4) were also inhibited by chrysin. These
results suggested that chrysin exerts its growth-inhibitory
effects either through activating p38-MAPK leading to the
accumulation of p21Waf1/Cip1 protein or through mediating
the inhibition of proteosome activity [47].
In another study by Woo et al. reported the chrysin-
mediated apoptosis in U-937 cancer cell lines. DNA fragmen-
tation assay of chrysin-treated cells after 12 hours showed
typical inter-nucleosomal fragmentation of DNA. FACS
analysis of treated cells showed marked increase of accumu-
lation of subG1 cells after 12 hours. Decreased proenzyme
level of caspase-3 after chrysin treatment indicated the
importance of activated caspase-3 in apoptosis. Further the
activation of phospho-lipase C-γ (PLC-γ), a down stream
target of caspase-3 in chrysin treated cells confirmed the role
of caspase-3 in chrysin treated U937 cells. Western blotting
analysis of chrysin treated cells indicated the reduction in
the level of XIAP (a member of Inhibitor of Apoptosis
Proteins) and cytochrome c induction in dose dependent
manner. Mitogen activated protein kinase (MAPK) does not
have any role in the signaling pathway as shown by western
blot analysis, whereas Akt-signaling played significant role in
chrysin mediated apoptosis of U937 cells. It has been shown
that inhibition of Akt phosphorylation in U937 cells by
the specific PI3K inhibitor, LY294002, significantly enhanced
the apoptosis. Overexpression of a constitutively active Akt
(myr-Akt) in U937 cells inhibited the induction of apoptosis,
activation of caspase 3 and PLC-γ1 cleavage by chrysin [48].
Further Zheng et al. synthesized 13 derivatives of
chrysin and tested it for anticancer effect against human
gastric adenocarcinoma cell line (SGC-7901) and colorec-
tal adenocarcinoma (HT-29) cells. These derivatives were
formedmainly by alkylation, halogenation, nitration, methy-
lation, acetylation and trifluoromethylation. MTT assay
revealed that 5, 7-dimethoxy-8-iodochrysin and 8-bromo-
5-hydroxy-7-methoxychrysin have the strongest activities
against SGC-7901 and HT-29 cells respectively. The com-
pound 5, 7-Dihydroxy-8-nitrochrysin was found to have
strong activities against both SGC-7901 and HT-29 cells
[48]. Zhang et al. tried to improve the biological properties
of chrysin by synthesizing diethyl chrysin-7-yl phosphate
(CPE: C19H19O7P) and tetraethyl bis-phosphoric ester of
chrysin (CP: C23H28O10P2) though a simplified Atheron-
Todd reaction. In Mass spectroscopy analysis, CPE formed
complexes with lysozyme and hence phosphate esters of
chrysin enhanced the interaction with proteins compared
to unmodified chrysin. Cultured human (HeLa) cell lines
were treated by CR, CP and CPE with 10 μM for 24, 48,
and 72 hours. The Cell viability markedly declined in time-
dependent fashion. Moreover methyl green-pyronin stain-
ing, PCNA immunohistochemistry and TUNEL techniques
were also employed to study the effect of CR, CPE and CP
in the cultured HeLa cell lines. It favored their hypothesis
that all CR, CP and CPE could inhibit proliferation and
induce apoptosis in the following order of inhibition potency
CP > CPE > CR. Hence they suggested CP and CPE as a new
potential candidate for human cervical cancer [49].
3.1.3. Effect of Galangin in Leukemia Cancer Cell Line.
Charles et al. described the antiproliferative effect of galangin
on human leukemia (HL-60) cell line. Trypan blue exclusion
method indicated the remarkable decrease in the cell viability
after treating with 100 μM for 24 hours. Galangin of 1–10 μM
exerted antiproliferative effect which is evident after 48 hours
of incubation. Early and late apoptosis were detected using
annexin-V-FITC and PI staining using 100 μM galangin
and these results correlated with the results of trypan-
blue method reported already. Active caspase-3, a hallmark
of apoptosis process, was detected after 24 hours and
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72 hours of incubation with 50 and 10 μM of galangin
respectively. Cell cycle analysis indicated the increase in the
subG1 phase of galangin (>10 μM) treated cells. This was
illustrated further in DNA fragmentation assay, in which
they could observe typical ladder pattern after 24 hours of
100 μM galangin exposure. Forward and side scatter changes
were predominantly observed after 24 hours and 72 hours
incubation with 100 μM galangin. Galangin treated cells
displayed reduced forward scatter indicative of decreased
relative size, and enhanced side scatter indicative of increased
internal complexity. Rhodamine median florescence inten-
sity measured as an indicator of ROS levels, showed no
evidence for intracellular oxidative stress as a key-player
of cytotoxicity and significant phagocyte-like differentiation
was not detected [50].
3.1.4. Effect of Quercetin in Cancer Cell Lines. Kang et al.
investigated the role of quercetin as an anticancer agent
in HL-60 cells. From their experiments they inferred the
concentration dependent inhibition of HL-60 cell prolif-
eration between the ranges of 10 to 80 μM. They showed
cells incubated with 10 μM displayed inhibition on the
growth of HL-60 cells. It was 17.1%, 27.3%, 40.1%, and
52.7% after 24, 48, 72, and 96 hours of treatment. Cell
cycle analysis indicated that quercetin (20, 40, and 60 μM)
increased the number of cells in the G2/M phase from
7.6% to 12.4%, 19.1%, and 23.5% correspondingly, and
decreased the population of G0/G1, cells from 46.2% to
40.2%, 32.1%, and 34.5%, respectively, without significant
changes in the S-phase cell population after 24 hours of
treatment. Quercetin showed remarkable inhibitory effect
on the activities of cytosolic Protein Kinase C (PKC) and
membrane TPK of HL-60 cells in vitro, with IC50 values of
about 30.9 and 20.1 μM, respectively, but did not have the
effect on membrane PKC or cytosolic TPK activity. It has
also repressed the complete activity of phosphoinositides like
phosphatidylinositol (PI), phosphatidylinositol 4-phosphate
(PIP), and Phosphatidylinositol 4, 5-bisphosphate (PIP2) at
the concentration of 80 μM. Hence they concluded that the
inhibitory effect of quercetin on the growth of HL-60 cells
may be related to its inhibitory effects on PKC and/or TPK
in vitro and/or on the production of phosphoinositides [51].
Csokay et al. studied the effect of quercetin in K562 human
leukemia cells. Treatment with quercetin (5.5 μM) activated
both apoptosis and differentiation programs. After 1 hour
exposure to the drug it resulted in apoptosis of the leukemia
cells. Differentiation of K562 cells was observed atleast
after 12 hours of exposure. They attributed these effects to
the early downregulation of c-myc and Ki-ras oncogenes
and rapid reduction of Inositol-1, 4, 5-triphosphate (IPs)
concentrations [52].
Robaszkiewicz et al. illustrated the effect of quercetin in
A-549 cells. They found quercetin exerted both antioxidant
and pro-oxidant properties depending upon the concen-
tration used. Quercetin in low concentration (1–20 μM)
promoted the cell proliferation whereas higher concentration
(50–200 μM) showed the concentration dependent cytotoxi-
city. The lower concentration (10 μM) of quercetin produced
increased number of live cells, repressing the number of cells
in the apoptotic and necrotic portions. On the other hand if
the concentration was above 50 μM, it reduced the number
of live cells by increasing the apoptotic/necrotic fractions.
Quercetin decreased production of reactive oxygen species
in the cells producing peroxides in the medium. They also
found incubating with low concentrations of quercetin led
to a small increase in Total Antioxidant Capacity (TAC) of
cell extracts but higher concentrations of the quercetin led
to a progressive decrease in the TAC of cell extracts. Total
thiol content of the cells followed a pattern similar to TAC.
Hence they suggested that cellular effects of quercetin are
complex and include both antioxidant effects and induction
of oxidative stress due to formation of reactive oxygen species
in the extracellular medium [53]. In another study made
by Elizandra et al. substantiated that quercetin may act
differently on cancer and normal neuronal tissue. Quercetin
decreased the cell viability in glioma cell cultures resulting in
necrotic and apoptotic cell death. It also arrested the glioma
cells in the G2 checkpoint of the cell cycle, and decreased the
mitotic index. Furthermore, they demonstrated quercetin
was able to protect the hippocampal organotypic cultures
from ischemic damage. These results showed that although
it induced growth inhibition and cell death in the U138MG
human glioma cell line, still it has a cytoprotective effect in
normal cell cultures [54].
Indap et al. examined the antiproliferative effect of
quercetin both in vitro and in vivo. They showed quercetin
could exert antiproliferative effect against MCF-7 cell line
in a dose and time dependent manner with IC50 value of
10 μg/mL. Further quercetin was found to arrest the MCF-
7 cell growth in G2/M phase of cell cycle. Moreover it was
shown that quercetin inhibited the tumor growth by more
than 58% in mice grafted with mammary carcinoma and it
extended the survival ability of sarcoma 180 bearing mice by
2.3 times. Further quercetin enhanced the inhibitory effect
of mitomycin C in mammary adenocarcinoma. Finally they
concluded that these effects were mediated in part by the
often poorly vascularised and hypoxic regions of tumors
[55]. In a recent study initiated by Choi et al. studied
the anticancer effect of quercetin against breast cancer cell
(MDA-MB-435). MTT assay revealed that quercetin showed
inhibitory effect on MDA-MB-435 cell growth in a time
and dose dependent manner. Further cell cycle analysis of
quercetin treated cells showed significant increase in the
accumulation of cells at subG1 phase. Further quercetin
treatment increased Bax expression but decreased the Bcl2
levels. Cleaved caspase-3 and PARP expression were also
increased by quercetin [56].
3.1.5. Effect of Acacetin in Liver and Lung Cancer Cell Lines.
Hsu et al. investigated the antiproliferative effect of acacetin
in human liver cancer cell line (HepG2). The maximum
inhibitory effect (nearly 72%) was observed at a concentra-
tion 20 μg/mL after 48 hours. The IC50 value was observed to
be 10.44 μg/mL for the HepG2 cells. Flow cytometry results
indicated an increase in the G1 phase of cells from 31.1
to 61.6 and 76.5% at a concentration of 10 and 20 μg/mL,
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respectively. DNA fragmentation assay of cells treated with
acacetin indicated the number of cells undergoing apoptosis
increased to about 4-fold at 10 μg/mL and 8-fold at 20 μg/mL
after 48 hours. Further it has been demonstrated that
acacetin increased the induction of p53 and its downstream
target, p21/WAF1 as assayed by Enzyme linked Immuno-
sorbent assay (ELISA). Fas ligand assay indicated that FasL,
mFasL and sFasL increased in a dose-dependent manner.
Pro-apoptotic Bax protein level also increased due to acacetin
treatment at 24 and 48 hours. In their continuity study, they
examined the role of acacetin in human nonsmall cell lung
cancer A549 cells. They reported the antiproliferative effect
was significant in dose-dependent manner and the IC50 value
was found to be 9.46 μM. Cell cycle analysis of A-549 cells
treated with 5 and 10 μM of acacetin indicated an increase
in G1 phase from 34.7% to 42.6% and 61.2%, respectively.
Similarly DNA fragmentation assay indicated the number
of cells undergoing apoptosis increased from about 3.2-
fold to 8.1-fold at 5 and 10 μM of acacetin, respectively
after 48 hours. Similar to the observation in HepG2 cells,
acacetin increased the induction of p53 and its downstream
target, p21/WAF1 as assayed by Enzyme linked Immuno-
sorbent assay (ELISA). Fas ligand assay indicated that FasL,
mFasL, and sFasL increased in a dose-dependent manner.
They concluded that p53 and Fas/FasL apoptotic system
may participate in the antiproliferative activity of acacetin in
HepG2 and A549 cells [57, 58].
3.1.6. Effect of Kaempferol in Lung and Leukemia Cells.
Henry et al. explored the significance of Kaempferol induced
apoptosis in human lung nonsmall carcinoma cells (H460).
Trypan blue exclusion assay, demonstrated the varying
concentration of kaempferol reduced the cell viability in
the dose-dependent manner with an IC50 value of 50 μM.
Lactate dehydrogenase (LDH) assay indicated cell death is
due to apoptosis since there is no release of LDH enzyme
with the cells treated with kaempferol. ROS production is
not the cause for the cytotoxicity observed, since the oxidant-
sensitive fluorescent probe, CM-H2DCFDA signal does not
showed any change after kaempferol treatment. Mitochon-
drial membrane potential measured using fluorescent probe
3, 3′-dihexyl-oxacarbocyanine (DiOC6), a mitochondrion-
specific and voltage-dependent dye, indicated no change
after treating with kaempferol at varying concentrations for
16 hours. Kaempferol (50 μM) induced Apoptosis inducing
factor (AIF) from mitochondria to nucleus and elicited DNA
fragmentation and condensation in H460 cells. The levels of
pro-caspase 3 were decreasing after exposing to kaempferol
for 8 hours. Moreover protein levels of Mn SOD and Cu/Zn
SOD increased during treatment with 50 μM kaempferol for
24 hours [59].
Bestwick et al. reported the kaempferol antiproliferative
effect in the pro-myelocytic leukemia cells (HL60). Dose-
dependent inhibition of HL-60 was observed over 72 hours
exposure to kaempferol. FACS analysis reported that treat-
ment of cells with Kaempferol (10 μM) decreased the cell
growth. After 5 hours of treatment the proportion of cells
in S-phase increased compared to decrease in the G1 phase.
100 μM of kaempferol induced an initial accumulation in
S-phase and then G2/M as the time course progressed
from 48 to 96 hours. Phosphodityl serine exposure without
membrane damage as indicated by annexin V-FITC binding,
a feature of the early prenecrotic phase of apoptosis, was
only observed for a minor proportion of cells treated
with ≥20 μM kaempferol following either 24 hours or 72
hours treatments. After exposing the cells with kaempferol
for 24 and 72 hours, a decrease in the mitochondrial
potential followed by enhanced expression of active caspase-
3 was observed. Retinoic acid treatment results nearly 5%
differentiation of the cell population indicated by phorbol
12-myristate 13-acetate stimulated nitro blue tetrazolium
NBT reduction over 72 hours of treatment with 100 μM
of kaempferol. Multiparametric flow cytometric analysis
revealed distinct subpopulations of cells with decreased size,
typical of apoptosis and necrosis, possessing heightened
caspase-3 activity followed by decreased antiapoptotic Bcl2
expression and changes in the membrane asymmetry and
integrity. The remaining population had elevated active
caspase-3 but no change or a moderate increase in Bcl2
expression and no plasma membrane alterations. Hence
kaempferol growth inhibitory effect on HL-60 leukemia cells
is due to heterogeneous response mainly dominated by cell
cycle alternation although some degree of cytotoxicity results
from apoptotic as well as nonapoptotic process [60].
3.1.7. Role of Pinocembrin and Pinobanksin in Cancer
Cell Lines. Suresh Kumar et al. showed cytotoxicity of
pinocembrin against a variety of cancer cells including
normal lung fibroblasts with relative non toxicity to human
umbilical cord endothelial cells. Pinocembrin induced loss of
mitochondrial membrane potential (MMP) with subsequent
release of cytochome c and processing of caspase-9 and
-3 in colon cancer cell line HCT 116. The initial trigger for
mitochondrial apoptosis appears to be by the translocation
of cytosolic Bax protein to mitochondria [61]. Pinobanksin
has been reported to exert antioxidant activity by lowering
the Fe (II) induced lipid peroxidation as well as inhibit-
ing the mitochondria membrane permeability transmission
(MMPT) [62].
3.1.8. Effect of Apigenin in Cancer Cells. Apigenin belongs
to the flavonoid family and it is widely reported for its
antitumor effects in various cell lines. It had exerted antipro-
liferative effect against colon, breast, cervical, neuroblastoma
and liver cancer cell lines. Wang et al. studied the effect of
apigenin on the cell growth and cell cycle in the colon carci-
noma cell lines like SW480, HT 29 and Caco-2. Cell count
and protein content of the apigenin treated cells showed
reduction compared to the control. Apigenin inhibited the
cell growth with the IC50 values of 40, 50, and 70 μM for the
SW480, HT-29, and Caco-2 cells respectively. Flow cytomet-
ric analysis of apigenin (80 μM) treated cells resulted in G2/M
arrest of 64%, 42%, and 26% in SW480, HT-29, and Caco-
2 cells respectively. They had also reported the inhibition
of p34cdc2 kinase and cyclin B1 proteins in the apigenin
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Table 2: Summary of in vitro studies of honey polyphenols.
Compound Cell line tested Observation/result
Reference
no.
CA, MC,
PEDMC,
PEC
HT -29
Toxicity:
CA >2500 μM
PEC >60 μM
PEDMC >60 μM
MC >225 μM
Inhibition of DNA/RNA:
150 μM MC, 40 μM PEC and 20 μM PEDMC
TPK activity downregulation:
100 μM of MC, 30 μM of PEC and 20 μM of PEDMC
ODC activity downregulation:
150 μM MC, 40 μM PEC and 20 μM PEDMC
[38]
CAPE HeLa
Substance Inhibition percentage Concentration
DNA 95% 20μM
RNA 75% 20μM
Protein 47% 20μM
[40]
CAPE U-937
(a) Maximum inhibition of NFκB at 25 μg/mL after TNF treatment
(b) No inhibitory effect on AP-1, TFIID, and Oct-1
(c) Structural analogue 5, 6 dihydroxy strongly inhibited the NF-κB
[41]
CAPE C6 glioma
(a) DNA fragmentation at 50 μM after 24 hours
(b) p-p53 ↑, active Caspase 3↑, Bak and Bax ↑, Bcl2 ↓ [42]
CA, CAPE HepG2
(a) CA and CAPE inhibited MMP-2 and 9 with IC50 of 10–20 μM and
2–5 μM
(b) CA at the concentration of 200 μg/mL reduced the cell viability to 61%
viability compared to the controls, and the treatment with CAPE
(20 μg/mL) in HepG2 cells reduced the viability to 72% of the controls
[43]
CAPE HT 1080
(a) m-RNA levels of MMP-2 and MMP-9 were inhibited ↓
(b) m-RNA levels of TIMP-1 and MT-1 MMP level decreased ↓ [44]
Chrysin C-6 glioma
(a) 72 hours of incubation with 50 μM of chrysin, inhibited ↓ 90% of
cell-proliferation
(b) p21Waf1/Cip1 levels increased ↑, CDK2 and CDK4 were inhibited ↓
[47]
Chrysin U-937
(a) PLC-γ and active Caspase-3 level increased ↑
(b) XIAP level decreased ↓ whereas cytochome-C level ↑ [48]
Galangin HL-60
(a) Galangin of 1–10 μM also promoted antiproliferative effect which is
evident after 48 hours of incubation
(b) Active Caspase 3 ↑, a hallmark of apoptosis process, was detected after
24 hours and 72 hours of incubation with 50 and 10 μM of galangin
respectively
(c) Cell cycle analysis indicated the increase in the subG1 phase ↑ of
galangin (>10 μM) treated cells
[50]
Quercetin HL-60
(a) Quercetin had a remarkable inhibitory effect ↓ on the activities of
cytosolic PKC and membrane TPK from HL-60 cells in vitro, with IC50
values of about 30.9 and 20.1 μM, respectively
(b) Quercetin repressed ↓ the complete activity of phosphoinositides like
PI, PIP, and PIP2 at the concentration of 80 μM
[51]
Quercetin A-549
(a) Quercetin in low concentration (1–20 μM) promoted the cell
proliferation ↑ whereas higher concentration (50–200 μM) showed the
concentration dependent cyotoxicity ↓
(b) Increase in TAC ↑ of cell extracts but higher concentrations of the
quercetin led to a progressive decrease in the TAC ↓
[53]
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Table 2: Continued.
Compound Cell line tested Observation/result
Reference
no.
Quercetin K562
(a) reduction of c-myc and Ki-ras oncogenes ↓
(b) fall in Inositol-1,4,5-triphosphate (IPs) concentrations ↓ [52]
Quercetin Glioma cell
(a) arrested the glioma cells in the G2 checkpoint of the cell cycle
(b) decreased the mitotic index [54]
Quercetin MCF-7
(a) IC50 value of 10 μg/mL
(b) cell cycle arrest at G2/M phase
(c) inhibited the tumor growth by more than 58% in mice grafted with
mammary carcinoma
[55]
Acacetin HEPG2
(a) IC50 value = 10.44 μg/mL
(b) p53 ↑, p21Waf1 ↑, FasL ↑, mFasL ↑, sFasL ↑ and Bax ↑ [58]
Acacetin A-549
(a) IC50 value = 9.46 μM
(b) p53 ↑, p21Waf1 ↑, FasL ↑, mFasL ↑, sFasL ↑ and Bax ↑ [57]
Kaempferol HL-60
(a) Mitochondrial potential decreased ↓ caspase-3 level increased ↑
(b) Kaempferol growth inhibitory effect on HL-60 leukemia cells is due to
heterogeneous response mainly dominated by cell cycle alternation
although some degree of cytotoxicity results from apoptotic as well as
nonapoptotic process
[60]
Pinocembrin HCT116
(a) Mitochondrial potential decreased ↓
(b) BAX translocates in to mitochondria
(c) Cyt-C release
(d) Caspase-3 and Caspase 9 level increased (↑)
[61]
Pinobanksin
Rat liver
Mitochondria
(a) Inhibits the mitochondria membrane permeability transition ↓
(b) Lowers the lipid peroxidation ↓ [62]
Apigenin Colon cancer
(a) inhibition of p34cdc2 kinase
(b) cyclin B1 ↓
(c) IC50 values:
HT 29 = 50 μM
SW480 = 40 μM
Cac0-2 = 70 μM
[63]
Apigenin Breast Cancer
(a) inhibiting the HER2/neu-overexpressing cells (MDA-MB-453 cells)
compared to basal level HER2/neu-expressing cells (MCF-7) [64]
Apigenin Hela
(a) IC50 = 35.89 μM
(b) p21/WAF1 ↑
(c) p53 and caspase-3 increased ↑
(d) Bcl2 decreased
[65]
Apigenin Neuroblastoma
(a) EC50 = 35 μmol/L in NUB-7
(b) EC50 = 22 μmol/L in LAN-5
(c) p53 and p21WAF1/CIP1 ↑
(d) Bax ↑
[66]
Apigenin Liver cancer
(a) IC50 was observed to be 8.02 μg/mL for HepG2, 2.16 μg/mL for Hep3B
and 22.73 μg/mL for PLC/PRF/5
(b) G2/M cell cycle arrest
(c) Increase of p53 and p21/WAF1 ↑
[67]
treated cells [63]. Way et al. demonstrated the antiprolif-
erative nature of apigenin against breast cancer cells. They
reported that apigenin was found to be more potent in
inhibiting the HER2/neu-overexpressing cells (MDA-MB-
453 cells) compared to basal level HER2/neu-expressing
cells (MCF-7). For instance, 40 μM of apigenin resulted in
48% inhibitory effect in MDA-MB-435 whereas in MCF-
7 it caused only 31% growth inhibition. They examined
the role of HER2/HER3-PI3K/Akt pathway in the apigenin
induced apoptosis and showed that it inhibited directly the
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PI3K activity first, consequently inhibiting the Akt kinase
activity. Moreover they demonstrated the inhibition of
HER2/neu autophosphorylation and transphosphorylation
resulting from depleting HER2/neu protein in vivo [64].
In another study by Zheng et al. elucidated the apoptosis
induced by apigenin in human cervical cancer cell HeLa.
It was found that apigenin could decrease the cell viability
with an IC50 of 35.89 μM.DNA fragmentation assay and flow
cytometric analysis of apigenin treated cells confirmed the
apoptosis induction. They had observed increased expression
of p21/WAF1 and p53. Further Fas/APO-1 and caspase-3
increase and Bcl2reduction in the apigenin treated HeLa
cells confirmed the apoptosis induction [65]. Torkin et al.
reported that apigenin could induce apoptosis in neurob-
lastoma cells like NUB-7 and LAN-5. Apigenin repressed
the cell viability in a dose-dependent manner in human
neuroblastoma cell lines with an EC50 = 35 μmol/L in NUB-
7, and EC50 = 22 μmol/L in LAN-5 after 24 hours. Moreover
it was found to inhibit the colony forming ability and
NUB-7 xenograft tumor growth in nonobese diabetic mouse
model. They had shown that apigenin induced apoptosis
was mediated though p53 as it enhanced the expression
of p53 and p53 induced gene products like p21WAF1/CIP1
and Bax [66]. Recent research by Chiang et al. suggested
the antiproliferative effect of apigenin in HepG2, Hep3B
and PLC/PRF/5 cells. It was found that apigenin could
inhibit the cell growth of the above reported liver cancer
cells but not the normal murine liver BNL.CL2 cells. IC50
was observed to be 8.02 μg/mL for HepG2, 2.16 μg/mL for
Hep3B and 22.73 μg/mL for PLC/PRF/5. In addition, DNA
ladder and flow cytometric analysis indicated apoptosis in
the HepG2 cells. Apigenin treated cells were arrested at G2/M
phase of the cell cycle. Further they observed increasing
accumulation of p53 and p21/WAF1 in the treated cells
[67].
4. Summary
Chemoprevention utilizes appropriate pharmacological
agents [3, 4] or of dietary agents, consumed in diverse
forms like macronutrients, micronutrients, or nonnutritive
phytochemicals. Various polyphenols are reported in
honey. Some of the polyphenols of honey like Caffeic
acid (CA), Caffeic acid phenyl ester (CAPE), Chrysin
(CR), Galangin (GA), Quercetin (QU), Acacetin (AC),
Kaempferol (KF), Pinocembrin (PC), Pinobanksin (PB) and
Apigenin (AP) have evolved as promising pharmacological
agents in treatment of cancer. The summaries of individual
polyphenols were tabulated under Table 2.
Caffeic acid has been reported as a carcinogen in initial
studies, but the same caffeic acid along with combination of
other antioxidant has been shown to suppress colon tumors
in rats. Chung et al. showed that oral administration of Caf-
feic acid and Caffeic acid phenyl esters (CAPE) reduced liver
metastasis, mediated by the dual inhibition of NF-κB and
MMP-9 enzyme activity [43]. Natarajan et al. demonstrated
that CAPE is known to have antimitogenic, anticarcinogenic,
antiinflammatory and immunomodulatory properties [41].
CAPE’s antiinflammatory and anticancer property has also
been shown to protect skin cells when exposed to ultra-violet
radiation and UVB radiation [46].
Weng et al. showed that the growth inhibitory effect
of chrysin in C6 glioma cells was either though activating
p38-MAPK which leads to the accumulation of p21Waf1/Cip1
protein or mediating the inhibition of proteasome activity
[47]. In another study by Woo et al. it has been elucidated
that chrysin induces apoptosis in association with the
activation of caspase-3 and Akt signal pathway, that plays
a crucial role in chrysin-induced apoptosis in U937 cells
[48]. Galangin expressed antiproliferative effect on HL-60
cells on dose dependent manner and also induced DNA
fragmentation without loss of membrane integrity [50].
Quercetin also inhibited the HL-60 cell proliferation in
association with the inhibition of cytosolic Protein Kinase
C (PKC) and membrane Tyrosine Protein Kinase (TPK)
in vitro [51]. It has been reported that quercetin in low
concentration promoted cell proliferation of A-549 cells,
whereas in higher concentration it inhibited cell proliferation
and survival [53]. Further quercetin exerted antiprolifer-
ative effect against glioma and breast cancer cells [54–
56].
Acacetin, another important flavanoid inhibited the
proliferation of A549 cells, induced apoptosis and blocked
the cell cycle progression at G1 phase. It also improved the
expression of p53 and Fas ligands [57]. In another study,
it has been shown to inhibit HepG2 cell proliferation and
provoke apoptosis by enhancing the p53 and Fas ligands as
in the case of A549 cells [58]. Kaempferol induced apoptosis
in H460 cells which was accompanied by significant DNA
condensation and increasing ATP levels. It also changed the
expression of Caspase 3 and Apoptosis Inducing Factor (AIF)
levels [59]. Bestwick et al. reported recently that kaempferol
growth inhibitory effect on HL-60 leukemia cells is due
to heterogeneous response mainly dominated by cell cycle
alternation although some degree of cytotoxicity results from
apoptotic as well as nonapoptotic process [60]. Pinocembrin
induced loss of mitochondrial membrane potential (MMP)
with subsequent release of cytochrome c and processing of
caspase-9 and -3 in colon cancer cell line HCT 116 [61].
Apigenin exerted antiproliferative effect against colon, breast,
cervical, neuroblastoma and liver cancer cell lines [63–67].
Our review has clearly demonstrated certain honey
polyphenols tested in laboratorial setups showed to be a
promising pharmacological agent for inhibiting cancer cell
proliferation. After generating more in-depth and exhaustive
information of these compounds jointly in in vitro and in
vivo studies, clinical trials have to be initiated to further
validate these compounds in medical applications.
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